CTLA4 and neoplasm: Consequently, SLR-LNPs inhibited tumor growthin an RIG-I-dependent manner in multiple poorly immunogenic solidtumor models and increased therapeutic responses to anti-PD-1 andanti-CTLA-4 ICIs.